RESEARCHDIAGNOSTICSTRANSLATIONOUTREACH
 
Miguel Melo
Name: Miguel Melo
E-mail: miguelm@ipatimup.pt
Extension: 
225570700
Academic Degree: PhD, MD


Miguel Melo
Miguel Melo
Member of
External Researcher of Cancer Signalling & Metabolism


Short CV
Academic background
Degree in Medicine (MD), Medical Faculty of Coimbra, Portugal (2000)
Specialist in Endocrinology-Nutrition (2008)
Postgraduate course in Biomedicine – Medical Faculty of the University of Coimbra

Former status
Invited Assistant of Medical Genetics – University Hospital of Coimbra

Current status
Endocrinologist at the Department of Endocrinology, Diabetes and Metabolism – University Hospital of Coimbra, Portugal
Head of the Molecular Study and Diagnostic Unit - Department of Endocrinology, Diabetes and Metabolism – University Hospital of Coimbra, Portugal
Invited Assistant of Endocrinology – Medical Faculty of the University of Coimbra
PhD Student – Medical Faculty of the University of Coimbra / Ipatimup

Highlights
Biomarkers of prognosis and treatment selection in differentiated thyroid carcinomas.
Radioiodine treatment of differentiated thyroid carcinomas.

Supervisor of

PI (running)

PI (closed)
First Author
 
C
IF
1. Melo M, Gavina C, Silva-Nunes J, Andrade L, Carvalho D
Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link? Diabetology & metabolic syndrome 13: 81, 2021. [Review] 
 doi: 10.1186/s13098-021-00698-5 PMID: 34315528.
 
0
3.3 (*)
2. Melo M, Gaspar da Rocha A, Batista R, Vinagre J, Martins MJ, Costa G, Ribeiro C, Carrilho F, Leite V, Lobo C, Cameselle-Teijeiro JM, Cavadas B, Pereira L, Sobrinho-Simões M, Soares P
TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease. The Journal of clinical endocrinology and metabolism 102: 1898-1907, 2017. [Article] 
 doi: 10.1210/jc.2016-2785 PMID: 28323937.
 
72
5.8
3. Melo M, Vicente N, Ventura M, da Rocha AG, Soares P, Carrilho F
The role of ablative treatment in differentiated thyroid cancer management Expert Review of Endocrinology & Metabolism 12: 109-116, 2017. [Review] 
 doi: 10.1080/17446651.2017.1289839.
 
1
-
4. Melo M, Cameselle-Teijeiro JM, Eloy C, Amendoeira I, Soares P, Caneiro-Gómez J, Sobrinho-Simões M
Therapeutic options Rare Tumors of the Thyroid Gland: Diagnosis and WHO Classification  107-110, 2017. [] 
 doi: 10.1007/978-3-319-61182-2_7.
 
0
-
5. Melo M, da Rocha AG, Vinagre J, Sobrinho-Simões M, Soares P
Coexistence of TERT Promoter and BRAF Mutations in Papillary Thyroid Carcinoma: Added Value in Patient Prognosis? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33: 667-8, 2015. [Letter] 
 doi: 10.1200/JCO.2014.59.4614 PMID: 25605839.
 
30
21.0
6. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, Castro P, Prazeres H, Lima J, Amaro T, Lobo C, Martins MJ, Moura M, Cavaco B, Leite V, Cameselle-Teijeiro JM, Carrilho F, Carvalheiro M, Máximo V, Sobrinho-Simões M, Soares P
TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas. The Journal of clinical endocrinology and metabolism 99: E754-65, 2014. [Article] 
 doi: 10.1210/jc.2013-3734 PMID: 24476079.
 
374
6.2
7. Melo M, Costa G, Ribeiro C, Carrilho F, Martins MJ, da Rocha AG, Sobrinho-Simões M, Carvalheiro M, Soares P
Stimulated Thyroglobulin at Recombinant Human TSH-Aided Ablation Predicts Disease-free Status One Year Later. The Journal of clinical endocrinology and metabolism 98: 4364-72, 2013. [Article] 
 doi: 10.1210/jc.2013-2267 PMID: 24037891.
 
32
6.3
8. Melo M, Costa G, Carrilho F, Soares P
Radiotherapy: radioiodine and external beam irradiation treatment of differentiated thyroid carcinomas Clinical Management of Thyroid Cancer  78-92, 2013. [] 
.
 
0
-
Senior Author
 
C
IF
@ 2014 Ipatimup Institute of Molecular Pathology and Immunology of the University of Porto
A
A
A

Send Email
From
To
Subject